Sports sponsorships are almost a $20 billion business in North America alone. Yet, despite the significant academic and corporate interest in such high financial stakes, the literature is equivocal on several key aspects. While some papers report that sports sponsorships enhance shareholder value, others dispute this. Furthermore, the marketing determinants of this value are unclear, particularly the role of firms’ marketing capabilities. To address these, the authors first created a database of sports sponsorship announcements over 19 years by Canadian and U.S. firms, complementing it with the stock market and firm-level financial and marketing data. The authors then conducted an event study and found that investor response to sports sponsorship announcements is, on average, positive. The authors found that investors not only credit firms with higher marketing capabilities, amplifying their positive reaction, but that they also seem to use firms’ marketing capabilities to offset the potential barriers to the value generated from these announcements. Specifically, for investors, the firms’ marketing capabilities can compensate for the dampening effect of financial risk. Our results are robust to considerations of sample selection bias, endogeneity, and outliers.
7 February 2023 in Journal of Product Innovation Management
Prior research has highlighted the performance implications of R&D alliances for innovation outcomes and the financial returns of firms. However, research on R&D alliances has yet to offer insights into how the premature termination of such alliances, before fulfilling their predetermined innovation objectives, affects the shareholder returns of the firm. Applying transaction cost economics (TCE) theory and real options (RO) logic to a post‐formation alliance setting, we posit that premature termination of R&D alliances prompts relative volatility in investors' prospective benefits and risks. Employing an event study analysis method and using a sample of 116 premature alliance termination announcements in the biopharmaceutical industry, we observe an average negative abnormal stock return of 3.21% for focal firms. Further, our analyses reveal that investors respond even more adversely to alliances terminated unilaterally by the partner of the focal firm in which they invested than those terminated through mutual agreements or by the focal firm itself. Also, we find that alliance duration from formation to termination mitigates the negative effect of termination on shareholder returns.
19 October 2024 in Journal of Organizational Computing and Electronic Commerce